By Dr. Quoc Dang, DO — Medical Director, WeightLossPills.com

Starting a GLP-1 medication is not a one-time decision followed by a prescription and no further contact. At least it should not be. The patients I see who do best are in regular communication with their physician throughout treatment, not because something is going wrong but because active monitoring is part of what makes this kind of treatment work well and stay safe.

Yet I regularly see patients who were started on medication by a provider who did not order baseline labs, did not schedule follow-up appointments, and essentially handed over a prescription with minimal guidance. That is not good obesity medicine, and it puts patients at a disadvantage.

Here is what appropriate monitoring looks like.

Baseline Labs Before You Start

Before beginning GLP-1 therapy, a responsible physician should obtain a baseline metabolic panel. This includes fasting blood glucose and hemoglobin A1C to establish where your blood sugar sits, a full lipid panel, a comprehensive metabolic panel covering liver and kidney function, and thyroid function tests.

These labs serve two purposes. First, they screen for contraindications and conditions that require careful management during treatment. Second, they give you and your doctor a baseline against which to measure improvement. One of the most rewarding parts of monitoring GLP-1 therapy is watching metabolic markers normalize over the course of treatment, but that story only makes sense if you know where you started.

Thyroid Considerations

GLP-1 receptor agonists carry a black box warning regarding medullary thyroid carcinoma, a rare form of thyroid cancer that has been observed in rodent studies at high doses. Patients with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 should not take these medications.

For patients without that history, routine thyroid cancer screening is not indicated, but thyroid function should be checked at baseline given the prevalence of thyroid disease in the population, and rechecked if a patient develops symptoms suggestive of thyroid dysfunction during treatment.

Blood Sugar and Diabetes Medication Adjustments

GLP-1 medications are potent glucose lowering agents. In patients who are also taking diabetes medications, particularly sulfonylureas or insulin, the combination can cause hypoglycemia. This requires active management, often including dose reductions of the diabetes medication as GLP-1 therapy takes effect.

I check hemoglobin A1C at baseline and again at three months and six months for patients with prediabetes or diabetes. In patients with significant diabetes medication regimens, I may check fasting glucose more frequently, particularly in the early months when the effects are most pronounced.

Kidney and Liver Function

Weight loss is generally excellent for both kidney and liver health. Nonalcoholic fatty liver disease, which is closely linked to obesity, often shows meaningful improvement on GLP-1 therapy. I follow liver function tests in patients with known fatty liver disease, and I am always pleased when we see those enzymes normalize.

For patients with preexisting kidney disease, GLP-1 medications require more careful monitoring. Recent data has been generally reassuring about their safety in chronic kidney disease, but dose adjustments or extra surveillance may be warranted depending on the degree of impairment.

Pancreatitis Monitoring

There is an association between GLP-1 medications and acute pancreatitis, though the absolute risk remains low. Patients with a history of pancreatitis should discuss this risk carefully with their physician before starting. For patients without that history, I ask at every visit about new abdominal pain, particularly pain that radiates to the back or is accompanied by nausea, which can be early signs of pancreatic inflammation.

I also check amylase and lipase at baseline and periodically throughout treatment in patients who report abdominal symptoms. Most of what I see turns out to be gastrointestinal motility effects from the medication rather than pancreatitis, but the distinction matters.

Blood Pressure and Cardiovascular Markers

One of the most clinically meaningful benefits of GLP-1 therapy is cardiovascular risk reduction. The SELECT trial demonstrated a 20 percent reduction in major cardiovascular events in patients with obesity and established cardiovascular disease who were treated with semaglutide. Tracking blood pressure, heart rate, and lipids throughout treatment allows patients and physicians to document this improvement.

Patients who come to their physician armed with an understanding of what weight loss medication should involve in terms of monitoring are better prepared to ask the right questions and advocate for thorough care. This is not a passive treatment. It works best when patients and physicians are actively engaged throughout.

The Follow-up Schedule

In my practice, I see patients one month after starting treatment to assess tolerability and side effects, then every three months thereafter for the first year. At each visit I review weight, body composition when possible, blood pressure, and any symptoms. Labs are typically repeated at three months and six months, then annually if everything is stable.

This kind of structured follow-up is not bureaucratic overhead. It is how good outcomes get built. The patients who thrive in treatment are the ones who show up, communicate openly about what is working and what is not, and allow their regimen to be adjusted thoughtfully over time.

It’s affect on mental health also.

Dr. Quoc Dang, DO, is a board-certified physician and Medical Director at WeightLossPills.com, where he specializes in medically supervised weight management and GLP-1 therapy.